Traps for the Unwary: The Impact of the False Claims Act on Start-Up and Venture-Stage Life Sciences Companies

By Karen S. Lovitch

A government investigation or enforcement action can disrupt a business, delay the launch of a new product, or threaten funding. Life sciences companies that participate in federal grant programs need to be aware of the risks associated with non-compliance with rules and regulations governing those programs. On November 20, 2013, Karen Lovitch, David Barmak, Kevin McGinty, and Scott Samuels of Mintz Levin will present a webinar to identify best practices for managing employees and fostering compliance in a growth company environment.

Click here to register for the webinar.

Subscribe To Viewpoints

Published

    • Viewpoint Topics

  • Health Care

    • Professionals

  • Karen S. Lovitch

    • Author

    Karen S. Lovitch

    Chair, Health Law Practice & Chair, Health Care Enforcement Defense Practice

    Karen advises industry clients on regulatory, transactional, operational, and enforcement matters. She has deep experience handling FCA investigations and qui tam litigation for laboratories and diagnostics companies.